Sign In
Buy JNJ
$241.00
+1.92 (+0.80%)
At Close: Jun 24, 2026
Dean Omar Branham Shirley's Partners Named to List of 500 Leading Lawyers in America
01:06pm, Monday, 13'th Jan 2025
DALLAS--(BUSINESS WIRE)--Dean Omar Branham Shirley, a plaintiff firm known for aggressively advocating for the rights of consumers, announced that name partners Jessica Dean and Trey Branham have been
Drugmakers rush to sign deals on first day of industry conference
12:07pm, Monday, 13'th Jan 2025
Drugmakers signed deals worth at least $18 billion in combined value on Monday, the first day of the healthcare industry's top conference in San Francisco.
Lost Money on Johnson & Johnson(JNJ)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky
10:30am, Monday, 13'th Jan 2025
NEW YORK, NY / ACCESSWIRE / January 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ("Johnson & Johnson") (NYSE:JNJ) concerning possible viol
Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal
10:03am, Monday, 13'th Jan 2025
On Monday, Johnson & Johnson JNJ agreed to acquire Intra-Cellular Therapies Inc. ITCI for $132.00 per share in cash for a total equity value of approximately $14.6 billion.
NEW YORK, NY / ACCESSWIRE / January 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson ("J&J" or "the Company") (NYSE:JNJ). In
Intra-Cellular just downgraded at Morgan Stanley, here's why
09:58am, Monday, 13'th Jan 2025
Intra-Cellular +32.2 (+33.94%) Johnson & Johnson +1.38 (+0.97%)
Johnson & Johnson makes $15 billion bet on mental-health drugs
07:13am, Monday, 13'th Jan 2025
Pharma giant Johnson & Johnson is buying Intra-Cellular Therapies, eying sales growth above analysts' expectations through 2029.
J&J to buy Intra-Cellular Therapies for $14.6 billion
06:38am, Monday, 13'th Jan 2025
Johnson & Johnson said on Monday it would buy drugmaker Intra-Cellular Therapies for about $14.6 billion, boosting its presence in the market for neurological disorder treatments.
Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.
06:30am, Monday, 13'th Jan 2025
NEW BRUNSWICK, N.J. & BEDMINSTER, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) and Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) announced today that they have entered into a definitive agreem
2 Beaten-Down Dividend Stocks to Buy in 2025
06:09am, Monday, 13'th Jan 2025
Dividend stocks are great for various reasons, and it's even better to invest in them while they are going through a rough patch, provided there are good reasons to believe they will recover. This des
This Stock Is Soaring Amid J&J Takeover Report
05:41am, Monday, 13'th Jan 2025
A deal could be reached for the biotech company this week, according to a media report.
Johnson & Johnson eyes $10bn acquisition of Intra-Cellular Therapies
04:16am, Monday, 13'th Jan 2025
Johnson & Johnson (NYSE:JNJ) is reportedly in talks to acquire neuroscience-focused biotech firm Intra-Cellular Therapies for $10bn. If completed, the deal would mark the largest biotech acquisition s
J&J explores bid for Intra-Cellular Therapies, Bloomberg News reports
04:35pm, Sunday, 12'th Jan 2025
Johnson & Johnson is exploring a bid to acquire Intra-Cellular Therapies Inc , a biopharmaceutical company, Bloomberg News reported on Sunday citing people familiar with the matter.
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Johnson & Johnson (JNJ)
11:00am, Sunday, 12'th Jan 2025
NEW YORK, NY / ACCESSWIRE / January 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ("Johnson & Johnson") (NYSE:JNJ) concerning possible viol
Bronstein, Gewirtz & Grossman, LLC Encourages Johnson & Johnson (JNJ) Investors to Inquire about Securities Investigation
10:00am, Sunday, 12'th Jan 2025
NEW YORK, NY / ACCESSWIRE / January 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson ("J&J" or "the Company") (NYSE:JNJ). In
